HOME arrow News & PR

News & PR

ReGenTree Announces the Results of the ARISE-2 Trial With RGN-259 for the Treatment of Dry Eye: Significant Efficacies Were Confirmed in Both Signs and Symptoms

2017.10.31

ReGenTree Announces the Results of the ARISE-2 Trial With RGN-259 for the Treatment of Dry Eye: Significant Efficacies Were Confirmed in Both Signs and Symptoms

(if you want to view the body of article, click on the bottom link)

https://www.newswire.com/news/regentree-announces-the-results-of-the-arise-2-trial-with-rgn-259-for-20023743